Rapamycin (Off-Label Use)
PharmaceuticalThe medical evidence (score 42) lags far behind community enthusiasm (score 68), as clinical studies provide no proof of lifespan extension in humans [s2, s8], while self-experimenters report optimistically based on animal data and subjective well-being [c1, c2]. This gap reflects a typical "pre-study-to-mainstream" pattern within the biohacking community.
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Rapamycin is the only compound that robustly extends lifespan in mammals — but that data comes from animal models, and controlled human longevity trials are still absent. As a prescription-only drug in Germany, off-label use for longevity is legally possible but clearly irresponsible without medical supervision and regular lab monitoring (glucose, lipids, kidney function, blood count). Side effects including mouth ulcers, increased infection susceptibility, dyslipidemia, and glucose intolerance are not rare — Bryan Johnson's public discontinuation due to exactly these issues is a warning the community should not dismiss. Importing rapamycin without a prescription is illegal.
Description
Prescription-only mTOR inhibitor; trialed off-label as a longevity agent – robustly extends mouse lifespan, human evidence still limited [s1, s2, s5].
Rapamycin (sirolimus) is a macrolide antibiotic originally isolated from the soil bacterium Streptomyces hygroscopicus on Easter Island (Rapa Nui) [s11]. It has been approved in the EU since 2001 as an immunosuppressant for the prevention of organ rejection following kidney transplantation [s12]. Since the discovery that rapamycin significantly extends the lifespan of mice even when treatment is initiated at the equivalent of the human 60th year of life [s3], it has been intensively researched as a potential longevity agent. The NIA Interventions Testing Program (ITP) demonstrated a median lifespan extension of 9% (males) and 14% (females) in genetically heterogeneous mice [s3, s4]. In humans, initial clinical data are available: a cohort study of 333 adults documented off-label use with weekly or biweekly administration of typically 5–6 mg and reported predominantly good tolerability [s6]. The PEARL trial (n=104, 1 year, double-blind) showed significant improvements in pain scores in women in the 10 mg group, as well as indications of favorable changes in body composition, without serious adverse events [s7]. However, a systematic review in Lancet Healthy Longevity (2023) concluded that evidence for rapalog-mediated slowing of aging in humans remains limited [s8]. Important limitations: No RCT has yet demonstrated that rapamycin extends human lifespan or clearly slows the aging process [s2, s8]. Long-term safety data for healthy adults are lacking [s7]. Immunosuppression, metabolic changes, and infection risk are documented risks [s1, s9].
Legal Status (DE)
In Germany, sirolimus (Rapamune®) is approved as a prescription-only medicinal product – exclusively for prophylaxis of organ rejection following kidney transplantation and for certain oncological indications [s11, s12]. Off-label prescribing for longevity promotion in healthy adults is legally permissible but not covered by any marketing authorization. Personal importation without a medical prescription is illegal. Rapamycin is not marketable as a dietary supplement [s12].
Mechanism of Action
Rapamycin first forms a complex with the intracellular binding protein FKBP12. This complex binds directly to the mTORC1 complex (mechanistic Target of Rapamycin Complex 1) and allosterically inhibits its kinase activity [s1, s13]. mTORC1 is a central sensor of nutrient and energy availability: under sufficient supply, it stimulates protein synthesis (via S6K1 and 4E-BP1) and cell growth while simultaneously inhibiting autophagy (via ULK1 complex phosphorylation) [s1]. mTORC1 inhibition induces the following processes: 1. Autophagy: degradation of damaged proteins and organelles is activated, regarded as a central geroprotective mechanism [s1]. 2. Slowing of cell growth and anabolic protein synthesis. 3. Partial immunomodulation: inhibition of T-cell proliferation and mTORC1-dependent immune cell activation; at low doses, possible improvement of immunosenescence [s2, s5]. 4. Energy metabolism: effects on insulin sensitivity and lipid metabolism – however, at higher doses, glucose intolerance and dyslipidemia may occur [s9]. At higher or sustained doses, rapamycin can also inhibit mTORC2 (indirect effect), leading to undesirable metabolic and immunological consequences [s13]. The weekly dosing interval in off-label use is intended to minimize mTORC2 inhibition while still allowing sufficient mTORC1 inhibition [s6, s9].
Dosing
Longevity / Gesundheitsspanne (wöchentlich)
- Dose
- 5–6 mg sirolimus
- Frequency
- 1× wöchentlich
- Route
- oral
- Duration
- fortlaufend, unter ärztlicher Aufsicht
- Timing
- Same day of the week, with or without food (maintain consistency)
- With food
- optional
Longevity (zweiwöchentlich, konservativeres Protokoll)
- Dose
- 5–10 mg sirolimus
- Frequency
- 1× alle 2 Wochen
- Route
- oral
- Duration
- fortlaufend, unter ärztlicher Aufsicht
- Timing
- Consistent dosing interval
- With food
- optional
Immunseneszenz (klinische Studie, Rapalog)
- Dose
- 0.5 mg daily or 5 mg weekly everolimus (rapalog)
- Frequency
- täglich oder wöchentlich
- Route
- oral
- Duration
- 6 Wochen
- Timing
- Per Mannick et al. study protocol
- With food
- optional
No officially established upper limit for off-label longevity use. Transplantation target doses of 2–5 mg/day with trough-level monitoring (5–15 ng/mL) are not transferable to off-label longevity use [s11]. Individual experts caution against >10 mg/week without close laboratory monitoring [s9].
Grapefruit juice and Seville oranges should be avoided due to CYP3A4 inhibition [s11]. Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can dramatically increase levels; inducers (rifampicin) reduce them substantially [s11]. Blood count, renal function, lipids, and glucose should be monitored regularly [s7, s9].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Mundgeschwüre / Aphthen (orale Mukositis) Frequently described in transplant and epilepsy cohorts; also reported by users at low off-label doses [s1, s9]. | gelegentlich | leicht |
| Erhöhte Infektionsanfälligkeit (v.a. Atemwegsinfektionen) Immunosuppressive effect may lead to increased infection rate; dose-dependent, observed even at low longevity doses [s2, s9]. | gelegentlich | moderat |
| Verzögerte Wundheilung mTORC1 inhibition reduces cell proliferation and tissue repair; relevant prior to surgical procedures [s1, s10]. | gelegentlich | moderat |
| Glukoseintoleranz / erhöhter Nüchternblutzucker At higher or daily doses: inhibition of the insulin signaling pathway via S6K1-IRS1 feedback; less pronounced with weekly low doses [s9]. | gelegentlich | moderat |
| Dyslipidämie (erhöhte Triglyzeride, LDL) Reported in 30–72% of patients in transplantation studies under therapeutic doses; extent at longevity doses unclear [s9]. | gelegentlich | moderat |
| Hautausschlag / Akne Common adverse effect in clinical approval studies [s11]; also reported at low doses. | gelegentlich | leicht |
| Ödeme (Beine, periphere Schwellungen) Known adverse effect from transplantation studies; mechanism partly via albumin alterations [s11]. | gelegentlich | leicht |
| Anämie / Thrombozytopenie Hematological adverse effects have been documented in transplant cohorts; less frequent at longevity doses [s11]. | selten | moderat |
| Erhöhtes Risiko für neue Diabetes mellitus Typ 2 Hazard ratio 1.36–1.9 in transplant populations under therapeutic doses; relevance for low off-label doses unclear [s9]. | selten | schwer |
| Pneumonitis (nicht-infektiöse Lungeninflammation) Known class-effect of mTOR inhibitors; rare but potentially severe; requires immediate medical evaluation [s11]. | selten | schwer |
Contraindications
Immunosuppressive effect may worsen existing infections and predispose to opportunistic infections [s2, s9].
Teratogenicity demonstrated in animal models; sirolimus is contraindicated in pregnancy [s11].
Rapamycin is primarily metabolized hepatically via CYP3A4; significant risk of accumulation in severe hepatic insufficiency [s11].
Impaired wound healing due to mTORC1 inhibition; discontinuation prior to surgery recommended [s1, s10].
Anaphylactic reactions have been reported; absolute contraindication [s11].
Further immunosuppression in an already compromised immune system is strongly contraindicated [s9].
Interactions
Synergistic
Theoretically complementary effects via AMPK activation (metformin) and mTORC1 inhibition (rapamycin); combination investigated in animal models, human RCT data are lacking [s2].
In the NIA-ITP, the combination of rapamycin + acarbose showed greater lifespan extension in mice than either agent alone [s4]. Human data are lacking.
Berberine activates AMPK and inhibits mTOR via the Akt/mTOR signaling pathway, which can complementarily enhance the autophagy-promoting effects of rapamycin. The combination may produce additive senescence-suppressing effects. Human RCT data are currently lacking.
Fisetin acts as a senolytic and is used in longevity protocols together with rapamycin to eliminate senescent cells while simultaneously inhibiting mTOR-dependent aging processes. The combination addresses complementary hallmarks of aging. Clinical human data are limited.
Quercetin inhibits mTORC1 via AMPK activation and acts as a senolytic; in combination with rapamycin it can deepen autophagy and eliminate senescent cells. Animal studies and mechanistic data support this synergy.
Spermidine promotes autophagy via epigenetic mechanisms and is described as synergistic with rapamycin, which directly inhibits mTORC1. Both substances jointly enhance cellular recycling activity.
NAD⁺ precursors such as NMN optimize mitochondrial function and DNA repair, while rapamycin inhibits mTOR and promotes autophagy. Both substances address complementary hallmarks of aging and may be mutually complementary.
Curcumin demonstrably inhibits both mTOR complexes (mTORC1 and mTORC2) and can thereby complement the effect of rapamycin on mTOR-dependent signaling pathways. The combination may produce additive autophagy induction. Clinical data are lacking.
Caution
Can dramatically increase sirolimus plasma levels and raise the risk of toxicity; avoid combination [s11].
Lead to markedly reduced sirolimus levels with loss of efficacy [s11].
CYP3A4 inhibition increases sirolimus bioavailability unpredictably; avoid entirely [s11].
Staggered administration required (4 hours after cyclosporine); mutual pharmacokinetic interaction; higher rapamycin doses necessary upon cyclosporine discontinuation [s11].
Additive nephrotoxicity and immunosuppression; close monitoring required [s14].
Immunosuppression by rapamycin can impair the vaccine response to live vaccines and increase the risk of vaccine-strain disease [s9].
Leucine and other branched-chain amino acids directly activate mTORC1 via the Rag GTPase mechanism at lysosomes and can thereby attenuate the mTOR-inhibiting effect of rapamycin. High BCAA doses could counteract the longevity effect of rapamycin.
GH-releasing peptides such as ipamorelin increase GH and IGF-1 levels, which activate mTOR. This can counteract the mTOR-inhibiting longevity mechanism of rapamycin. Concurrent use should be critically evaluated.
CJC-1295 stimulates GH release, thereby increasing IGF-1, which activates mTOR. This mTOR activation directly opposes the mechanism of action of rapamycin as a longevity supplement. The combination produces pharmacologically antagonistic effects.
Studies
Tier A — High Evidence
Outcome: Influenza vaccine response as a marker of immunosenescence reversal
Effect Size: Everolimus 0.5 mg/day and 5 mg/week significantly improved influenza vaccine response (OR ~1.4–2.0); improvement in PD-1-negative T cell proportion
Outcome: Safety and healthspan metrics (body composition, pain, well-being)
Effect Size: Women in the 10 mg group: significant pain reduction at 24 weeks (md=6.765, p=0.011) and 48 weeks (md=8.071, p<0.001); no serious adverse events in the longevity dose group
Tier B — Moderate Evidence
Outcome: Effects of rapamycin/rapalogs on age-associated physiological changes in humans
Effect Size: Limited and heterogeneous evidence; some indications of improved immune function and physical performance; no evidence of lifespan extension
Outcome: Safety and self-reported health effects in off-label use
Effect Size: Mostly tolerable at 5–6 mg/week; lower self-reported COVID infection rate; some users reported mouth sores, infections
Tier C — Low Evidence
Outcome: Median and maximum lifespan
Effect Size: +9% (males) / +14% (females) median lifespan; treatment initiated at the equivalent of human age 60
Outcome: Lifespan extension by rapamycin alone vs. combination with acarbose
Effect Size: Combination of rapamycin + acarbose showed greater lifespan extension than monotherapy with either agent alone
Community Evidence
Top reported benefits
- Improved general well-being and energy
- Subjectively improved physical performance
- Lower perceived infection frequency (COVID) by self-report
- Multi-year use without serious adverse effects in some users
Top reported issues
- Mouth ulcers / aphthae (most common complaint)
- Increased susceptibility to infections in individual users
- High cost and difficulty obtaining without a prescription
- Subjectively no noticeable effect in some users
Many self-experimenters stress the necessity of medical supervision and regular blood tests [c1, c2]. German-language users display more cautious attitudes and emphasize legal uncertainties [c4]. There is a considerable information imbalance: positive anecdotes predominate while long-term risks remain unknown [c3, c4]. Bryan Johnson's public discontinuation due to blood sugar issues and increased infection susceptibility was extensively discussed in the community [c3].
Scientific Sources
- Rapamycin for longevity: the pros, the cons, and future perspectives
Melnik BC, John SM, Schmitz G, et al. (2025). Frontiers in AgingBDOI - Wound complications frequency in heart transplant recipients on mammalian target of rapamycin inhibitors: A meta-analysis
Garbade J, Barten MJ, Bittner HB, et al. (2023). Clinical TransplantationALink - RAPAMUNE (sirolimus) Prescribing Information
Pfizer Inc. (2022). US Food and Drug Administration / accessdata.fda.govALink - Transplantationsmedizin: Sirolimus erhält europäische Zulassung
Deutsche Apotheker Zeitung Redaktion (2001). Deutsche Apotheker ZeitungBLink - A novel rapamycin analog is highly selective for mTORC1 in vivo
Lamming DW, Ye L, Katajisto P, et al. (2019). Nature CommunicationsCDOI - Tacrolimus
Cooper JE, Wiseman AC (2023). StatPearls – NCBI BookshelfBLink - Rapamune (sirolimus): European Public Assessment Report (EPAR)
European Medicines Agency (2024). CLink - What is the clinical evidence to support off-label rapamycin therapy in healthy adults?
Kritchevsky SB, Beavers KM, Miller ME, et al. (2023). Aging (Albany NY)BLink - Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison DE, Strong R, Sharp ZD, et al. (2009). NatureCPMID:19587680DOI - Exploring the Anti-aging Potential of Acarbose and Rapamycin: Insights from the NIA Interventions Testing Program
Strong R, Miller RA, Bogue M, et al. (2022). Aging CellCLink - mTOR inhibition improves immune function in the elderly
Mannick JB, Del Giudice G, Lattanzi M, et al. (2014). Science Translational MedicineAPMID:25355697DOI - Evaluation of off-label rapamycin use to promote healthspan in 333 adults
Kaeberlein M, Bhupinder A, Galvan V, et al. (2023). GeroScienceBPMID:37191826DOI - Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results
Kaeberlein M, Galvan V, Bhupinder A, et al. (2024). Aging (Albany NY)APMID:40188830 - Targeting ageing with rapamycin and its derivatives in humans: a systematic review
Arriola Apelo SI, Pumper CP, Goodman JA, et al. (2023). The Lancet Healthy LongevityADOI - Blazing a trail for the clinical use of rapamycin as a geroprotecTOR
Kadam M, McElwee M, Bhupinder A, et al. (2023). Aging CellBLink
Community Sources
Storage
Unopened
Store cool (2–8 °C) or at room temperature (max. 25 °C), protected from light and moisture.
Opened
Oral solution should be used within 1 month of opening; tablets should be stored in the original sealed blister pack.
Notes
The oral solution of Rapamune contains ethanol; do not freeze. Tablets are stable at room temperature. Follow manufacturer instructions [s11].